Back to News
Market Impact: 0.32
Sofwave Receives NMPA Approval in Mainland China
Source: GlobeNewswire
Healthcare & BiotechProduct LaunchesRegulation & Legislation
China's NMPA approved the product following a 200-subject randomized controlled trial that showed statistically significant improvement in mid-to-lower facial wrinkles. The study also reported a favorable safety profile, supporting commercialization potential in the Chinese aesthetics market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
More News
- Nvidia's CEO turmoil gives newly empowered Democrats fresh ammunition in pursuit of oversight
- Paraguay raids ex-president’s home: Why a bank crash brought down Pena
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Musk says Tesla will refund some Cybertruck deposits, defends decision to end production
- UniCredit CEO Plots Commerzbank Governance Overhaul
- Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion